Drug Profile
PG 101
Alternative Names: PG-101; Pro-ocularTMLatest Information Update: 20 May 2021
Price :
$50
*
At a glance
- Originator Glia LLC.
- Developer Glia LLC.; Ora Inc; PharmaDax; Rhodes Pharmaceuticals
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dry eyes; Graft-versus-host disease
Most Recent Events
- 20 May 2021 Phase-II clinical trials in Dry eyes (In adults, In the elderly) in Taiwan (Ophthalmic) (NCT04884217)
- 19 May 2021 Phase-II clinical trials in Graft-versus-host disease (Ophthalmic) (Glia LLC website,
- 03 Feb 2016 No recent reports on development identified - Phase-I/II for Dry eyes in USA (Ophthalmic, gel suspension)